Pay in 4 interest-free payments of $21.25 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
Lodoxamide Study Group
2020 Jul 9
Smiles: C1CN(CCCCC2=NNN=N2)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21
JUN90152 shows 150-fold selectivity for SMS2 over SMS1 (IC50 of 1000 nM)
6-dihydropyridin-3-yl)phenyl]-1
Avatrombopag Catalog No.:M11396-10 Lodoxamide Study GroupAvatrombopag, also known as AKR 501, YM477, AS 1670542 or E5501, is a novel orally active thrombopoietin (TPO) receptor agonist. AKR 501 specifically targeted the TPO receptor and stimulated megakaryocytopoiesis throughout the development and maturation of megakaryocytes just as rhTPO did. AKR 501 may be useful in the treatment of patients with thrombocytopenia. Avatrombopag was first approved in 2018. Product information CAS Number: 570406 98 3